Tomas G. Olsson

The impact of demographic, clinical, genetic, and imaging variables on tau PET status

M. Gorno-Tempini, M. Pontecorvo, C. Sudre, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease

W. Jagust, M. Gorno-Tempini, M. Pontecorvo, 2021, JAMA neurology.

Predicting diagnosis and cognition with 18F-AV-1451 tau PET and structural MRI in Alzheimer's disease

Rik Ossenkoppele, Niklas Mattsson, Oskar Hansson, 2019, Alzheimer's & Dementia.

Modeling Strategies for Quantification of In Vivo 18F-AV-1451 Binding in Patients with Tau Pathology

Rupert Lanzenberger, Andreas Hahn, Oskar Hansson, 2017, The Journal of Nuclear Medicine.

Increased basal ganglia binding of 18 F‐AV‐1451 in patients with progressive supranuclear palsy

M. Schain, O. Hansson, C. Nilsson, 2016, Movement disorders : official journal of the Movement Disorder Society.

In Vivo Veritas - 18F-radiolabeled glycomimetics allow insights into the pharmacological fate of galectin-3 inhibitors.

V. Shalgunov, M. Herth, U. Nilsson, 2019, Journal of medicinal chemistry.

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation.

G. Rabinovici, O. Hansson, Ruben Smith, 2016, Journal of Alzheimer's disease : JAD.